Disc Medicine (IRON) vs Pharvaris N.V. (PHVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pharvaris N.V. (PHVS) has outperformed Disc Medicine (IRON) over the past year, gaining 41.2% versus a loss of 9.9%. Over five years, PHVS leads with a +100.5% price change compared with -45.2% for IRON. Disc Medicine is the larger company by market cap ($2.33 billion vs $2.18 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRON | PHVS |
|---|---|---|
| Share price | $60.77 | $31.12 |
| Market cap | $2.33B | $2.18B |
| 1-day change | -0.67% | -1.77% |
| YTD return | -22.96% | +14.16% |
| 1-year return | -9.88% | +41.18% |
| 5-year return | -45.18% | +100.51% |
| EPS (TTM) | $-6.58 | $-3.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $99.50 | $43.25 |
| 52-week low | $40.00 | $20.65 |
| Distance from 52-week high | -38.92% | -28.05% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.77% | +83.87% |
| Average volume | 462.73K | 731.42K |
| Shares outstanding | 38.39M | 70.20M |
| Employees | 165 | 148 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PHVS has outperformed IRON by 51.1 percentage points over the past year.
About Disc Medicine
IRON stock →Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 165 employees
About Pharvaris N.V.
PHVS stock →Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant.
Health Care · Biotechnology: Pharmaceutical Preparations · 148 employees
IRON vs PHVS FAQ
Which is bigger, Disc Medicine or Pharvaris N.V.?
Disc Medicine (IRON) is larger, with a market capitalization of $2.33B compared with $2.18B for Pharvaris N.V. (PHVS).
Which stock has performed better over the past year, IRON or PHVS?
PHVS returned +41.18% over the past 12 months, compared with -9.88% for IRON (price return, excluding dividends). Past performance does not predict future results.
Are Disc Medicine and Pharvaris N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.